Henry Schein, Inc. (HSIC) has seen significant action lately, with various partners either acquiring or selling substantial
shares in the company. Companies such as
Isthmus Partners LLC,
Bridgewater Associates LP,
FORA Capital LLC,
Quantbot Technologies LP, and the
Bank of Montreal have all respectively played a role in this action. Activism has also entered the picture, as
Ananym Capital seeks changes at the company. HSIC's
acquisition of
Acentus signals further expansion into homecare medical products. Given the quarter performance and future prospects, analysts and
Wall Street remain bullish on
Henry Schein. It also reported on its Q3 2024 earnings, displaying strength despite
cyber incidents. Despite some losses, the firm's
stock gains have outperformed competitors, suggesting sturdy investor confidence. Noticeably, on a philanthropic front,
Henry Schein made it to FORTUNE® Magazine’s ‘Change the World’ list and raised considerable funds through its Practice Pink Program dedicated to cancer patients.
Henry Schein HSIC News Analytics from Tue, 07 May 2024 07:00:00 GMT to Sat, 30 Nov 2024 11:09:58 GMT -
Rating 6
- Innovation 4
- Information 9
- Rumor 1
